Effect of anti-VEGF antibody on retinal ganglion cells in rats

British Journal of Ophthalmology

Volumn 91, Issue 9, 2007, Pages 1230-1233

  Iriyama, Aya ^a   Chen, Yi Ning ^a   Tamaki, Yasuhiro ^a   Yanagi, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 120; VASCULOTROPIN 144; VASCULOTROPIN 164; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; EYE TOXICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA DISEASE; RETINA GANGLION CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL COUNT; CELL DEATH; CELLS, CULTURED; INJECTIONS; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 34548331324     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.117309     Document Type: Article

References (18)

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-18.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
3. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-8.
4. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
5. Feiner L, Barr EE, Shui YB, et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-8.
6. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90:1316-21.
7. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-18.
8. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic antivascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006;281:6625-31.
9. Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 2006;1762:1109-21.
10. Sopher BL, Thomas PS Jr, LaFevre-Bernt MA, et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF 164 in the motor neuron degeneration. Neuron 2004;41:687-99.
11. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 2006;26:12439-46.
12. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998;39:972-81.
13. Iriyama A, Uchida S, Yanagi Y, et al. Effects of indocyanine green on retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45:943-7.
14. Brewer GJ, Torricelli JR, Evege EK, et al. Optimized survival of hippocampal neurons in B27-supplementea Neurobasal, a new serum-free medium combination. J Neurosci Res 1993;35:567-76.
15. Mizuno K, Koide T, Yoshimura M, et al. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 2001;42:688-94.
16. Enaida H, Sakamoto T, Hisatomi T, et al. Morphological and functional damage of the retina caused by intravitreous indocyanine green in rat eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:209-13.
17. Ueno S, Kondo M, Piao CH, et al. Selective amplitude reduction of the PhNR after macular hole surgery: ganglion cell damage related to ICG-assisted ILM peeling and gas tamponade. Invest Ophthalmol Vis Sci 2006;47:3545-9.
18. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-9.